CD274 and neoplasm: In a single-arm phase 2 trial, patients with oligometastatic NSCLC (≤4 metastases either at diagnosis or after initial local treatment), regardless of PD-L1 expression, who had completed LAT to all tumor sites and were immunotherapy-naïve, were treated with pembrolizumab for up to 8 cycles.